stockrow
Friday 6 November 2026
Export NEOG’s income statement to Excel — free account
Neogen Corporation
NEOG Healthcare Medical Devices
Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025.
- Revenue
- +6.50%
- EPS
- −129.4%
- Free cash flow
- +135.6%
- Total debt
- −2.31%
Quarter to August 2026, against a year earlier
11.79
0.11
+0.94%
Follow NEOG
Alert me
| Older periods | Nov '25 | Feb '26 | May '26 | Aug '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.46 | 2.79 | 2.23 | 2.85 | |
P/FCF ratio |
0.00 | 385.29 | 60.63 | 50.53 | |
P/Operating CF |
66.01 | 106.92 | 64.24 | 195.44 | |
P/B ratio |
0.61 | 1.15 | 0.93 | 1.21 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.22 | 3.54 | 2.95 | 3.56 | |
EV/EBITDA |
19.72 | 35.22 | 25.10 | 26.98 | |
EV/Operating CF |
29.53 | 44.38 | 30.86 | 36.84 | |
EV/FCF |
(109.37) | 488.90 | 80.24 | 62.98 | |
Quick Ratio |
1.89 | 1.97 | 2.10 | 2.06 | |
Current Ratio |
3.91 | 3.92 | 3.82 | 3.90 | |
Net Debt/EBITDA |
28.62 | 24.27 | 15.73 | 20.69 | |
Debt/Assets |
23.60% | 23.62% | 23.72% | 23.44% | |
Debt/Equity |
0.38 | 0.38 | 0.38 | 0.37 | |
Asset Turnover |
0.24 | 0.24 | 0.26 | 0.26 | |
Operating CF/Net income |
(1.22) | (1.34) | (2.68) | (1.08) | |
Capex/Depreciation |
(0.42) | (0.39) | (0.11) | (0.27) | |
Interest Coverage |
(0.36) | (0.24) | 0.24 | (0.13) | |
Research and Development Expense of Revenue |
2.03% | 1.80% | 2.19% | 2.92% | |
Selling, General and Administrative Expense of Revenue |
47.84% | 46.64% | 44.25% | 45.24% | |
Intangible Assets out of Total Assets |
0.72 | 0.71 | 0.71 | 0.71 | |
Share Based Compensation of Revenue |
1.91% | 0.52% | 1.33% | 1.39% | |
Graham Net Nets |
(0.53) | (0.27) | (0.33) | (0.25) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(46.79%) | (25.11%) | (0.34%) | (2.16%) | |
Free Cash Flow Yield |
(1.39%) | 0.26% | 1.65% | 1.98% | |
Revenue per Share |
1.03 | 0.97 | 1.04 | 1.02 | |
Operating CF per Share |
0.09 | 0.10 | 0.14 | 0.06 | |
Capex per Share |
(0.05) | (0.05) | (0.02) | (0.04) | |
Free Cash Flow per Share |
0.04 | 0.05 | 0.12 | 0.02 | |
Cash per Share |
0.67 | 0.73 | 0.85 | 0.79 | |
Shareholders Equity per Share |
9.68 | 9.66 | 9.62 | 9.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.68 | 9.66 | 9.62 | 9.57 | |
Free Cash Flow |
7.83 | 11.17 | 26.20 | 4.70 | |
Working Capital |
427.53 | 439.40 | 446.40 | 433.00 | |
Capital Expenditures |
(11.67) | (11.53) | (4.00) | (8.20) | |
Net Current Asset Value |
(680.89) | (666.60) | (648.50) | (634.30) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.05 | 0.02 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
148.04 | 148.58 | 150.10 | 137.33 | |
Average Payables |
71.31 | 73.72 | 79.35 | 77.10 | |
Average Inventory |
180.52 | 183.57 | 167.55 | 169.76 | |
Average Assets |
3,707.02 | 3,697.67 | 3,394.90 | 3,340.68 | |
Average Common Equity |
2,386.78 | 2,381.37 | 2,082.05 | 2,102.52 |
Columns are period end dates · fundamentals updated 2 Nov 2026